No Association of Plasma Levels of Adiponectin and c-peptide with Risk of Aggressive Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort

Victoria L. Stevens; Eric J. Jacobs; Juzhong Sun; Susan M. Gapstur

doi:10.1158/1055-9965.EPI-14-0114

DOI: 10.1158/1055-9965.EPI-14-0114 Published May 2014

Article Figures & Data

Tables

Table 1.

Characteristics of the prostate cancer cases and matched controls from the CPS-II Nutrition Cohort

	Controls (N = 272)	Cases (N = 272)
Variable	N (%)	N (%)
Age at blood draw
≤65	51 (18.7)	50 (18.3)
66–70	90 (33.1)	90 (33.1)
71–75	77 (28.3)	81 (29.8)
76+	54 (19.9)	51 (18.8)
Race
White	271 (99.6)	271 (99.6)
Black	1 (0.4)	1 (0.4)
Family history of prostate cancer^a
Yes	31 (11.4)	50 (18.4)
Diabetes^b
Yes	33 (12.1)	27 (9.9)
BMI (kg/m²)^b
<25	112 (41.2)	101 (37.1)
25–<30	108 (39.7)	128 (47.1)
30+	47 (17.3)	41 (15.1)
Missing	5 (1.8)	2 (0.7)
Physical activity (METs/wk)^a
<7	76 (27.9)	75 (27.6)
7–<17.5	108 (39.7)	112 (41.2)
17.5–<24.5	38 (14.0)	48 (17.7)
24.5+	48 (17.7)	34 (12.5)
Missing	2 (0.7)	3 (1.1)
History of PSA testing^a
Never	24 (8.8)	40 (14.7)
Within 2 years	192 (70.6)	180 (66.2)
>2 years	30 (11.0)	28 (10.3)
Unknown	26 (9.6)	24 (8.8)
Gleason score
6 or 7 (3+4)		27 (9.9)
7 (4+3)		108 (39.7)
8		73 (26.8)
9–10		46 (16.9)
Unknown		18 (6.6)
Stage^c
T2 (organ confined)		194 (71.3)
T3		44 (16.2)
T4		25 (9.2)
Unknown		9 (3.3)

Abbreviations: BMI, body mass index; METs, metabolic equivalents.

↵^aAs reported on 1997 questionnaire.
↵^bAs reported at time of blood draw (1998–2001).
↵^cUnknown category includes six cases defined as regional using SEER summary stage that corresponds to stage T3 or T4.

Table 2.

Association of adiponectin and c-peptide levels with prostate cancer in CPS-II

	All aggressive^a			High risk^b
Analyte	Cases	Controls	OR (95% CI)	Cases	Controls	OR (95% CI)
Adiponectin (ng/mL)
<6,178	62	68	1.00 (ref)	43	38	1.00 (ref)
6,178–<7,879	61	68	1.05 (0.62–1.78)	38	43	0.76 (0.38–1.52)
7,879–<11,109	86	68	1.43 (0.87–2.36)	55	43	1.10 (0.58–2.11)
≥11,109	63	68	1.11 (0.64–1.93)	36	48	0.70 (0.33–1.49)
P trend			0.59			0.56
c-peptide (ng/mL)
<2.95	72	68	1.00 (ref)	43	47	1.00 (ref)
2.95–<4.69	59	68	0.69 (0.42–1.16)	34	41	0.94 (0.48–1.82)
4.69–<6.55	60	68	0.77 (0.47–1.28)	39	42	0.95 (0.48–1.87)
≥6.55	80	67	1.18 (0.69–2.02)	55	41	1.41 (0.72–2.78)
P trend			0.44			0.31

NOTE: Model stratified on pairs and adjusted for family history of prostate cancer, body mass index, physical activity in metabolic equivalents (METs), total calcium intake, and energy intake.